Antiviral Chemistry and Chemotherapy
The article processing charge (APC) is $1,700 (+VAT where applicable*). From 1st September 2023, the article processing charge (APC) is $2,000.
The article processing charge (APC) is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.
Antiviral Chemistry & Chemotherapy is a peer-reviewed, open access journal that publishes research on all aspects of antiviral compounds, including their chemistry, therapeutic effects, biochemistry, pharmacology, mode of action and virology. The journal also publishes reviews, pointers, short communications, protocols and correspondence. Original research manuscripts are required to present rigorous and reproducible scientific methodologies, and a clear antiviral design rationale to be considered for publication. Manuscripts that report negative results are welcome as long as they conform to the above publication criteria.
| Andrea Brancale | Cardiff University, UK |
| Joana Rocha Pereira | Rega Institute for Medical Research, Belgium |
| Zlatko Janeba | Institute of Organic Chemistry and Biochemistry CAS, v.v.i., Czech Republic |
| Ge Meng | Fudan University, China |
| Katherine Seley-Radtke | University of Maryland, USA |
| Luigi Agrofoglio | Université d'Orléans, France |
| Graciela Andrei | University of Leuven, Belgium |
| Masanori Baba | Kagoshima University, Japan |
| Marcella Bassetto | Cardiff University, UK |
| María José Camarasa | Instituto de Química Médica, Spain |
| Erik De Clercq | Rega Institute for Medical Research, Belgium |
| Joseph Colacino | PTC Therapeutics, USA |
| Jerome Deval | Janssen Pharmaceuticals Inc, USA |
| Hugh Field | University of Cambridge, UK |
| Vyacheslav Filichev | Massey University, New Zealand |
| David Frick | University of Wisconsin-Milwaukee, USA |
| Brian Gowen | Utah State University, USA |
| Paul Griffiths | University College London, UK |
| Jennifer Hammond | Pfizer Inc., USA |
| Piet Herdewijn | University of Leuvan, Belgium |
| Brett Hurst | Utah State University, Utah, USA |
| Lak Shin Jeong | Seoul National University, South Korea |
| LS Jeong | Ewha Womans University, South Korea |
| John Kadow | Bristol-Myers Squibb, USA |
| Anastasia Khandazhinskaya | Russian Academy of Sciences, Russia |
| Klaus Klumpp | Roche Diagnostics, USA |
| Mark Krystal | Bristol-Myers Squibb, USA |
| Nicholas Meanwell | Bristol-Myers Squibb Pharmaceutical Research and Development, New Jersey, USA |
| Mario Milani | University of Milano, Italy |
| Michael Miller | Merck & Co., USA |
| Hiroaki Mitsuya | Center for Cancer Research, USA |
| Daniela Montesarchio | University of Naples Federico II, Italy |
| Johan Neyts | University of Leuven, Belgium |
| Michael Otto | Gilead Pharmasset, USA |
| John Oxford | Barts and The London School of Medicine and Dentistry, UK |
| Suzanne Peyrottes | Université de Montpellier, France |
| St. Patrick Reid, PhD | University of Nebraska Medical Center, Omaha, NE, USA |
| Claudia Riccardi | University of Naples Federico II, Italy |
| Daniel Ruzek | Institute of Parasitology, Czech Republic |
| Raymond Schinazi | Emory University, USA |
| Stewart Schneller | Auburn University, USA |
| Mario Sechi | University of Sassari, Italy |
| John Secrist III | Southern Research Institute, USA |
| Ashoke Sharon | Birla Institute of Technology, India |
| Romano Silvestri | University of Rome, Italy |
| Hiroshi Takaku | Chiba Institute of Technology, Japan |
| Bart Tarbet | Utah State University, USA |
| Lawrence Tiley | University of Cambridge, UK |
| Enzo Tramontano | University of Cagliari, Italy |
| Simon Tucker | Biota Pharmaceuticals Inc, Australia |
| Stanley Tyms | Virogen, UK |
| Martijn Van Hemert | Leiden University Medical Centre, The Netherlands |
| Anne-Mieke Vandamme | University of Leuven, Belgium |
| Mark von Itzstein | Griffith University, Australia |
| Zhengqiang Wang | University of Minnesota, USA |
| Wataru Watanabe | Kyushu University of Health and Welfare, Japan |
| Jan Weber | Institute of Organic Chemistry and Biochemistry, Czech Republic |
| Richard J Whitley | University of Alabama, USA |
| Holger Zimmerman | AiCuris GmbH & Co, Germany |
- Open Access
- Article processing charge (APC)
- Article Types
- Editorial policies
4.1 Peer Review Policy
4.2 Authorship
4.3 Acknowledgements
4.4 Funding
4.5 Declaration of conflicting interests
4.6 Research ethics and patient consent
4.7 Clinical Trials
4.8 Reporting guidelines
4.9 Data - Publishing policies
5.1 Publication ethics
5.2 Contributor's publishing agreement - Preparing your manuscript
6.1 Word processing formats
6.2 Artwork, figures and other graphics
6.3 Supplementary material
6.4 Reference style
6.5 English language editing services - Submitting your manuscript
7.1 ORCID
7.2 Information required for completing your submission
7.3 Corresponding author contact details
7.4 Permissions - On acceptance and publication
8.1 Sage Production
8.2 Continuous publication
8.3 Promoting your article - Further information
This Journal is a member of the Committee on Publication Ethics
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the journal’s submission site https://mc.manuscriptcentral.com/avcc to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.
Only manuscripts of sufficient quality that meet the aims and scope of Antiviral Chemistry & Chemotherapy will be reviewed.
As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Antiviral Chemistry & Chemotherapy is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.
For general information on open access at Sage please visit the Open Access page or view our Open Access FAQs.
2. Article processing charge (APC)
If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons licence.
The article processing charge (APC) is $1,700 (+VAT where applicable*). From 1st September 2023, the article processing charge (APC) is $2,000.
*If the paying party is based in the European Union, to comply with European law, value added tax (VAT) must be added to the APC. Providing a VAT registration number will allow an institution to be exempt from paying this tax, except for UK institutions.
Original article
Your abstract must not exceed 250 words, and must also be clear and comprehensible in its own right. Compound numbers and display item citations must not appear in the abstract. Your main manuscript should include the following sections: Introduction; Methods; Results; Discussion; References. Result and Discussion can be merged in a single section. Please note that the Materials and Methods section can be divided into Chemistry and Virology if appropriate. The supplier (with brief address including city, state and country) must be given for all laboratory equipment and materials. A disclosure statement is required.
Review
Reviews are usually commissioned but unsolicited reviews are welcomed. Articles will be assessed in-house and those considered suitable will be peer reviewed before an editorial decision is made. Reviews may be highly focused or cover a broad area, but the scope of the review should be briefly stated in the abstract and fully stated in the introduction. The word count will depend on the breadth of the topic, but the abstract should be no longer than 250 words. References selected for publication in the journal should be chosen for their importance, ease of access, and for the ‘further reading’ opportunities they provide. A disclosure statement is also required.
Protocol
Normal limits: ≤1,500 words
Original research Protocols describe assays, methods or techniques that are relevant for the Aims & Scope of AVCC. The Protocol should clearly describe the experimental procedure and be structured in abstract, introduction, materials and reagents (with detailed references), equipment, procedure, data analysis/ conclusions. Visual additions illustrating important steps of the Protocol are highly desirable, including figures, graphs, schemes and videos. The submitted Protocol should have been a part of a peer-reviewed research article by the authors, which should be referenced upon submission.
Pointer
Normal limit: ≤1,500 words
Pointers are scholarly articles of contemporary interest. The aim of a Pointer is to highlight a new research direction normally arising from one’s own research or series of publications; to comment on a topical issue or situation; or to briefly review an article, expanding on the underlying themes and commenting on its significance in changing future research or therapy. As such articles point to the future, this will involve, necessarily, the author or authors’ personal opinion. Most are commissioned, although unsolicited Pointers are welcomed. Articles will be assessed in-house and those considered suitable will be peer reviewed before an editorial decision is made. Your abstract should be no longer than 100 words.
References to all the important source documents should be included, and should be chosen for their importance, ease of access, and for the ‘further reading’ opportunities they provide. A disclosure statement and abstract (<100 words) are also required. For advice on length please contact the Editorial Office.
Short communication
Normal limits: ≤1,500 words
Original research findings that do not require a full paper, but are completed studies, may be submitted as a short communication. Your abstract must not exceed 250 words, and must also be clear and comprehensible in its own right. Compound numbers and display item citations must not appear in the abstract. Your main manuscript should include the following sections: Introduction; Methods; Results; Discussion; References. All short communications should contain an introduction, methods, results and discussion section, and a disclosure statement is also required.
Workshop report
Normal limits: ≤1,500 words
The Journal encourages submissions on written reports from relevant and recent workshops and conferences. An abstract (<100 words) and disclosure statement are required.
Letter
Normal limits: ≤1,000 words
Letters are articles that address issues or exchange views on topics arising from published articles in Antiviral Chemistry & Chemotherapy. A disclosure statement is required.
Requirements for chemistry articles
Procedures used for the synthesis of novel compounds (where there is a specific antiviral rationale) together with spectral and analytical data establishing their structure and purity should be reported briefly in the Methods section and under the subheading Chemistry if appropriate. Authors should be concise and whenever possible use a format that describes general reaction conditions (only once), tabulating experimental data to afford effective presentation and economical use of space. The title of an experiment should include the chemical name of the product (preferably IUPAC nomenclature) and a compound number.
Compound numbers should be presented as a bold number, for example 1. Chemical compounds should be drawn in accordance with the 1996 American Chemical Society (ACS) settings. Additional analytical data required for refereeing may be deposited with the Editors as ‘supplementary data’. Data from X-ray diffraction studies for organic compounds or metal-organic compounds should be deposited with the Cambridge Crystallographic Data Centre (CCDC). Full details on deposition can be found at: http://www.ccdc.cam.ac.uk/products/csd/deposit/.
Following a preliminary triage to eliminate submissions unsuitable for Antiviral Chemistry & Chemotherapy all papers are sent out for review. The covering letter is important. To help the Editor in his preliminary evaluation, please indicate why you think the paper suitable for publication. If your paper should be considered for fast-track publication, please explain why. The journal’s policy is to have manuscripts reviewed by two expert reviewers.
Antiviral Chemistry & Chemotherapy utilizes a single-anonymize peer review process in which the reviewer’s name and information is withheld from the author.
As part of the submission process you will be asked to provide the names of peers who could be called upon to review your manuscript. Recommended reviewers should be experts in their fields and should be able to provide an objective assessment of the manuscript. Please be aware of any conflicts of interest when recommending reviewers. Examples of conflicts of interest include (but are not limited to) the below:
- The reviewer should have no prior knowledge of your submission
- The reviewer should not have recently collaborated with any of the authors
- Reviewer nominees from the same institution as any of the authors are not permitted
Please note that the Editors are not obliged to invite any recommended/opposed reviewers to assess your manuscript.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors.
The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
4.3.1 Third party submissions
Where an individual who is not listed as an author submits a manuscript on behalf of the author(s), a statement must be included in the Acknowledgements section of the manuscript and in the accompanying cover letter. The statements must:
• Disclose this type of editorial assistance – including the individual’s name, company and level of input
• Identify any entities that paid for this assistance
• Confirm that the listed authors have authorized the submission of their manuscript via third party and approved any statements or declarations, e.g. conflicting interests, funding, etc.
Where appropriate, Sage reserves the right to deny consideration to manuscripts submitted by a third party rather than by the authors themselves.
4.3.2 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance.
It is not necessary to disclose use of language polishing services.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Antiviral Chemistry & Chemotherapy requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the Sage Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
4.5 Declaration of conflicting interests
It is the policy of Antiviral Chemistry & Chemotherapy to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles.
Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’.
For guidance on conflict of interest statements, please see the ICMJE recommendations.
4.6 Research ethics and patient consent
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The Journal has adopted the ARRIVE guidelines.
Antiviral Chemistry & Chemotherapy conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives
Sage acknowledges the importance of research data availability as an integral part of the research and verification process for academic journal articles.
The journal is committed to facilitating openness, transparency and reproducibility of research, and has the following research data sharing policy. For more information, including FAQs please visit the Sage Research Data policy pages.
Subject to appropriate ethical and legal considerations, authors are encouraged to:
- share your research data in a relevant public data repository
- include a data availability statement linking to your data. If it is not possible to share your data, we encourage you to consider using the statement to explain why it cannot be shared.
- cite this data in your research
Sage is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the Sage Author Gateway.
Antiviral Chemistry & Chemotherapy and Sage take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
5.1.2 Prior publication
If material has been previously published, it is not generally acceptable for publication in a Sage journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the Sage Author Gateway or if in doubt, contact the Editor at the address given below.
5.2 Contributor's publishing agreement
Before publication Sage requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Antiviral Chemistry & Chemotherapy publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit Sage's OA licenses page.
Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
6.2 Artwork, figures and other graphics
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit Sage’s Manuscript Submission Guidelines.
Figures supplied in color will appear in color online.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplementary files.
Antiviral Chemistry & Chemotherapy adheres to the Sage Vancouver reference style. Please review the guidelines on Sage Vancouver to ensure your manuscript conforms to this reference style.
If you use EndNote to manage references, you can download the Sage Vancouver output file here.
6.5 English language editing services
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using Sage Language Services. Visit Sage Language Services on our Journal Author Gateway for further information.
Antiviral Chemistry & Chemotherapy is hosted on Sage Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/avcc to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
As part of our commitment to ensuring an ethical, transparent and fair peer review process Sage is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.
The collection of ORCID IDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID ID to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications.
If you do not already have an ORCID ID please follow this link to create one or visit our ORCID homepage to learn more.
7.2 Information required for completing your submission
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
7.3 Corresponding author contact details
Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
Please also ensure that you have obtained any necessary permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please see the Copyright and Permissions page on the Sage Author Gateway.
8. On acceptance and publication
If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been check for Sage Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 18 days. Please note that no production work will occur on your paper until the APC has been received.
Your Sage Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will made available to the corresponding author via our editing portal Sage Edit, or by email to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate.
One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The Sage Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice.
Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the Antiviral Chemistry & Chemotherapy editorial office as follows: